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Background
A growing body of evidence, in animals and humans,
suggest that IFNg plays a pathogenic role in primary
HLH (pHLH) and in secondary HLH, including macro-
phage activation syndrome. A pilot study in pHLH with
NI-0501, an anti-IFNg monoclonal antibody, is ongoing.
Mutations in NLRC4 have been recently reported to
cause recurrent MAS and an increased production of
IL-18, a cytokine known to induce IFNg.
Objectives
To report safety and efficacy of NI-0501 in a patient,
carrying a de novo NLRC4 mutation and presenting
with severe recalcitrant HLH.
Results
A 4.5 month-old Caucasian child presented at 20 days of
age with fever, rash hepatosplenomegaly, pancytopenia,
hypofibrinogenemia, hypertriglyceridemia, marked ferritin
and sCD25 increase. Severe liver insufficiency, followed by
multiorgan failure, required ICU admission. HLH diagno-
sis was based on 6 HLH-2004 criteria. Analysis of genes
involved in familial-HLH and functional tests (perforin
expression, degranulation and cytotoxicity) were negative.
Subsequent analysis of the NLRC4 gene showed a de novo
missense mutation (c.1010 C>A, encoding p.T337N),
absent in his parents. Elevated serum levels of IL-18 and
spontaneous IL-18 production were documented, confirm-
ing the relevance of the NLRC4 mutation. Treatment with
high-dose glucocorticoids and cyclosporine-A led to
progressive improvement. Development of sepsis trig-
gered an HLH reactivation with ICU admission. Treat-
ment with etoposide and/or ATG was not considered
because of active infections in an immunocompromised
child. Measurement of IFNg and of the IFNg-inducible
chemokines showed measurable serum levels of IFNg
and high serum levels of CXCL9 (5670 pg/ml) and
CXCL10 (4400 pg/ml). Compassionate use treatment
with NI-0501 was started on background dexametha-
sone (13.6 mg/m2) and cyclosporine-A. He received NI-
0501 for 3 months, initially every 3 days and subse-
quently every 7 days according to NI-0501 pharmacoki-
netics. No infusion reaction was observed. HLH clinical
and laboratory features progressively improved. Gluco-
corticoid tapering was rapidly initiated. After 3 months,
the child is in excellent conditions; all HLH clinical and
laboratory parameters have normalized. CRP occasion-
ally increases. Serum IL-18 levels remain elevated. High
circulating levels of IFNg complexed with NI-0501,
reflecting the high IFNg production are detectable, but
fully neutralized as shown by undetectable levels of
IFNg-inducible chemokines. He is receiving oral cyclos-
porine-A (6 mg/kg) and prednisone (0.3 mg/kg equiva-
lent to 0.9 mg/m2 of dexamethasone).
Conclusions
In a patient, carrying a de novo pathogenic NLRC4
mutation and presenting with severe recalcitrant HLH,
NI-0501 administration was well tolerated allowing con-
trol of all HLH features, while enabling glucocorticoid
tapering. No safety concern emerged.
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